Psychiatric and central nervous system (CNS) conditions constitute a huge area of unmet need with respect to drug therapy. Current treatments for these disorders leave much to be desired with regard to potency, suitability, reliability, and side effects; thus, efforts to develop new drugs in the CNS/psychiatric arena are intense. The single greatest indicator of this R&D focus is the ever-increasing stream of patent applications in the CNS/psychiatric field.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Intellectual property (IP), or more specifically patenting, represents unique scientific, commercial, and legal perspectives for evaluating the potential of a pharmaceutical company and its R&D assets. Trends in CNS/Psychiatric Drug Patenting: A Competitive and Pharmacological Assessment of Current and Projected R&D is a new report published by Decision Resources, Inc. This report demonstrates how patent activity information relating to psychiatric drug development can reveal patterns and trends with regard to disease indications, company strategies, and pharmacological mechanisms.

The analyses offered in this report are drawn from a custom database designed to facilitate competitive assessments and to spotlight licensing candidates in a critical area of CNS drug development. Key features of this report include the following:

  -- Analysis of trends in psychiatric drug patent activity over time by     disorder, pharmacological mechanism, and company.   -- Analyses of 11 psychiatric drug IP estates.   -- Three case studies of strategic uses of psychiatric drug patenting.   -- Profiles of companies that excel in specific areas of research or that     are best positioned to meet future development and launch targets-among     them Pfizer, AstraZeneca, Novartis, Lundbeck, Neurogen, Janssen, Glaxo     Wellcome, Neurosearch, Aventis, and Neurocrine Biosciences.    Trends in CNS/Psychiatric Drug Patenting is available for $3,500.00.  

Contact: Cindy Ohlman, 781.296.2521 (telephone), 781.296.2525 (fax), or ohlman@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, Inc., 781-296-2521, or
ohlman@dresources.com

Decision Resources Study Evaluates Emerging Therapies to Serve the Allergic Rhinitis Population

View Now